Navigation Links
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
Date:10/24/2008

Seeks Approval for Use in Epilepsy as Adjunctive Treatment in Partial Onset

Seizures

RARITAN, N.J., Oct. 24 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and older.

The filing is supported by data from three placebo-controlled clinical trials in patients with epilepsy. Results from the first study were presented at the Ninth EILAT Conference on Antiepileptic Drugs in June and results from two additional studies will be presented at the annual meeting of the American Epilepsy Society later this year.

In 1999, J&JPRD and SK Holdings Co., Ltd. (SK) entered into a license agreement to develop and commercialize carisbamate. J&JPRD received global marketing rights for the compound. If approved by the FDA, carisbamate will be marketed by Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Carisbamate has received provisional approval by the FDA to be marketed under the brand name of COMFYDE(TM).

About Partial Onset Seizures and Epilepsy

Epilepsy is one of the most common disorders of the nervous system, defined by recurrent unprovoked seizures. It is categorized as "primary generalized" or "partial onset" depending on the specific location of the abnormal electrical activity in the brain that typically characterizes the disorder. Partial-onset seizures are the most common type, and are generally more difficult to treat. Virtually any movement, sensory, or emotional symptom can occur as part of a partial seizure, including complex visual or auditory hallucinations. There are two categories of partial onset seizures: simple partial seizures (in which consciousness is retained), and complex parti
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
2. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
5. Johnson & Johnson Announces Changes to Accelerate Growth
6. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
7. Two-time Defending NASCAR Sprint Cup Series Champion Jimmie Johnson Joins the Team at CORD:USE Cord Blood Bank to Help Win the Race for Life
8. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
9. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
10. Craig Johnson Joins Ardea Biosciences Board of Directors
11. Migenix averts proxy contest; reaches agreement with DJohnson holdings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... MONTREAL , July 29, 2015 /PRNewswire/ - BioAmber Inc. ... Laurin , the Company,s Chief Financial Officer has resigned.  ... former Chief Financial Officer who retired in December 2014, ... search for a permanent successor.     Andy ... Mr. Laurin and ensure a smooth transition.  Andy was ...
(Date:7/29/2015)... 29, 2015  AsureQuality and Ubiquitome have agreed ... applications in food and primary production sectors. The ... PCR device, the Freedom4. AsureQuality provides ... the supermarket shelf for producers, processors and Competent ... animal disease control and pest management and surveillance ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an early ... is very pleased to announce that the Musculoskeletal Transplant ... agreed to invest in their seed round of development ... tissue storage capabilities. AmnioChor,s technology allows ... the human stem cells living within those tissues. Amnion ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... p.m. (Pacific); ... , SAN DIEGO, Nov. 7 ADVENTRX Pharmaceuticals,Inc. ... company,focused on commercializing proprietary product candidates for the treatment,of ... three-month and nine-month periods ended September 30, 2007. ...
... program draws on diverse group to advise on complex infertility ... ... Science,Center of the Bay Area (RSC) is launching an innovative advisory group,designed ... rare development in private medical groups in the,United States. RSC,s ethics ...
... Stock Exchange Symbol: MS, EDMONTON, Nov. 7 ... developer in the treatment of multiple sclerosis (MS), ... (DSMB) for the,Company,s phase II MINDSET-01 trial of ... safety analysis and recommended that,the trial continue as ...
Cached Biology Technology:ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 2ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 3ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 6ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 7California IVF Experts Tap Ethics Committee for Guidance 2BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... to the life of all organisms, insuring that each new ... copy of the genome. Among the legions of proteins that ... DNA-slicing "flap endonuclease" FEN1 plays a key role. ... an international team of scientists led by the U.S. Department ...
... is available in German . , Insects ... of odor molecules in the air are sufficient to be ... receptor proteins, expressed in these neurons recognize the odors. The ... electrical signals that are processed in the insect brain and ...
... Barbara, Calif.) Studies of the small sea squirt may ... bone marrow transplants in humans, according to scientists at UC ... every day waiting for transplants, due to the shortage of ... for organ transplants in the U.S. alone. Currently, only one ...
Cached Biology News:Secrets of a precision protein machine 2Secrets of a precision protein machine 3Secrets of a precision protein machine 4Secrets of a precision protein machine 5Molecular messages from the antennae 2Studies of marine animals aim to help prevent rejection of transplanted organs 2
... The SYS203 is a complete, flexible ... in small samples, as is frequently ... is designed around Instechs miniature Clark-style ... an inch in diameter (3.2 mm), ...
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
... The GSTTag Monoclonal Antibody is a ... affinity to the 26 kDa glutathione-S-transferase ... This purified antibody is suitable for ... sequence expressed in E. coli , ...
... The MetaVue Imaging System is the cost-effective ... With commands tailored to common research imaging ... morphometric analysis and simple image analysis. ... control library means that MetaVue has the ...
Biology Products: